Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by SERB Pharmaceuticals

SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding
From SERB Pharmaceuticals
Via GlobeNewswire
First FDA-approved treatment for severe frostbite now commercially available in the US
From SERB Pharmaceuticals
Via GlobeNewswire
SERB Pharmaceuticals expands leading emergency care portfolio with acquisition of Aurlumyn™ (iloprost IV) for severe frostbite
From SERB Pharmaceuticals
Via GlobeNewswire
FDA has accepted a BLA for bentracimab, the first and only ticagrelor reversal agent, for filing and priority review
From SERB Pharmaceuticals
Via GlobeNewswire
SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million
From SERB Pharmaceuticals
Via GlobeNewswire
SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics
From SERB Pharmaceuticals
Via GlobeNewswire
SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent
From SERB Pharmaceuticals
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.